Categories: AlternativeDataDevelopmentFinTechHealthTechLegalTechMedTechPlatformPropertyRobotics
KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of NT-814 as a breakthrough medicine for the treatment of chronic debilitating Women’s Health. NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd a separate legal entity. The new company will advance the development of NT-814 into Phase 2b in the lead indication PMS while also exploring its potential in other Women's Health conditions. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company.
Investors 4
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.08.2018 | Series C | $32.59M | - |
Mentions in press and media 6
| Date | Title | Description |
| 06.03.2020 | Что такое FemTech: полный обзор экосистемы стартапов для женщин | Все говорят про FinTech, EduTech, AgroTech, но на vc.ru не нашлось ни одного упоминания об одном из самых растущих сегментов среди технологических компаний в категории Digital Health — FemTech, или Female Technologies.
23 23 комментария
559... |
| 30.08.2018 | Term Sheet — Thursday, August 30 | 5 Qs WITH A DEALMAKER
Venture capitalist Ashmeet Sidana believes that some of the best Silicon Valley companies owe their success to a technical insight.
Paid Content Securing the enterprise without boundaries From ExtraHop
His firm, Engine... |
| 29.08.2018 | KaNDy Therapeutics Raises £25M in Series C Financing | KaNDy Therapeutics, a Stevenage, England, UK-based clinical-stage Women’s Health company, closed a £25m Series C financing round.
Backers included new US investor Longitude Capital, and life sciences investors Advent Life Sciences, Fountain... |
| 29.08.2018 | UK-based KaNDy Therapeutics raises $32.5 million Series C round, led by US firm | The company plans to use the money to fund a multinational Phase IIb dose-ranging clinical trial of its lead product candidate, NT-814, starting in the fourth quarter of this year, with topline results expected late next year. The study is ... |
| 27.09.2017 | NeRRe splits in two, carving out women’s health company | U.K. biotech NeRRe Therapeutics has decided to streamline its R&D portfolio by setting up a brand-new company focusing on women’s health.
The new company, called KaNDy Therapeutics, makes its official debut today and will handle the dev... |
| - | UK-based KaNDy Therapeutics raises $32.5 million Series C round, led by US firm | A British firm developing non-hormonal treatment for symptoms of menopause has raised £25 million ($32.5 million) in a Series C funding round led by US venture capitalists.
Stevenage, England-based KaNDy Therapeutics said it raised the fina... |
Reviews 0
